Parties d'ouvrages collectifs (5)
  1. 1. Süli-Vargha, H., Medzihradszky-Schweiger, H., Nagy, L., Morandini, R., & Ghanem, G. E. (1999). Melanotropin fragments containing difluoromethylornithine: synthesis and cytotoxicity. In Y. Shimonoshi (Ed.), Peptide science: Present and future (pp. 678-680). Kluwer Academic publishers.
  2. 2. Andry, G., Ghanem, G. E., Hamdi, M., Lothaire, P., Sales, F., & Deraemaecker, R. (1998). Salvage surgery for cutaneous melanomas of the head and neck. In M. Hamdi & J. Alvarez Vincent (Eds.), On head and neck oncology (pp. 627-632). Bologna, Italy: Monduzzi Edts.
  3. 3. Ghanem, G. E., Loir, B., Pector, J. C., Ewalenko, P., Kerger, J., Fruhling, J., Lienard, D., Lejeune, F., & Deraemaecker, R. (1997). Evaluation of serum Protein S-100 as a new melanoma marker. In P. Altmeyer, K. Hoffman, & M. Stücker (Eds.), Skin cancer and UV radiation (pp. 1136-1144). Springer.
  4. 4. Lienard, D., Lejeune, F., Autier, P., Sales, F., & Ghanem, G. E. (1994). Physiological and pharmacokinetics parameters in isolation perfusion of the limbs. In F. Lejeune, P. Chaudhuri, & T. Das Gupta (Eds.), Malignant melanoma: medical and surgical management (pp. 241-248). NY, USA: McGraw-Hill, Inc.
  5. 5. Ghanem, G. E., Lejeune, F., & Vercammen, A. (1987). Alpha melanocyte stimulating hormone in human melanoma. In U. Veronesi, N. Cascinelli, & M. Santinami (Eds.), Cutaneous melanoma: Status of knowledge and future perspective (pp. 637-638). London: Academic Press.
    6.   Articles dans des revues avec comité de lecture (167)
  6. 1. Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G. E., Saussez, S., & Journé, F. (2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer cell international, 24(1), 8. doi:10.1186/s12935-023-03196-y
  7. 2. Delbart, W., Marin, G., Stamatopoulos, B., De Wind, R., Sirtaine, N., Demetter, P., Vercruyssen, M., Woff, E., Karfis, I., Ghanem, G. E., Flamen, P., & Wimana, Z. (2023). Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Cancers (Basel), 15(8). doi:10.3390/cancers15082332
  8. 3. Kehagias, P., Kindt, N., Krayem, M., Najem, A., Agostini, G., Acedo Reina, E., Bregni, G., Sclafani, F., Journé, F., Awada, A., Ghanem, G. E., & Hendlisz, A. (2022). Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. Cells, 11(22), 3663. doi:10.3390/cells11223663
  9. 4. Delbart, W., Karabet, J., Marin, G., Penninckx, S., Derrien, J., Ghanem, G. E., Flamen, P., & Wimana, Z. (2022). Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy. International journal of molecular sciences, 23(20). doi:10.3390/ijms232012369
  10. 5. Marin, J., Journé, F., Ghanem, G. E., Awada, A., & Kindt, N. (2022). Cytokine Landscape in Central Nervous System Metastases. Biomedicines, 10(7), 1537. doi:10.3390/biomedicines10071537
  11. 6. Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11(7), 1157. doi:10.3390/cells11071157
  12. 7. Krayem, M., Ghanem, G. E., & Van Gestel, D. (2022). Recent advances in radiosensitivity determinants in melanoma. Current opinion in oncology, 34(2), 131-138. doi:10.1097/CCO.0000000000000818
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>